8-K Filing Pushes Marina Biotech, Inc. (OTCMKTS:MRNA) Up

[[tagnumber 0]][[tagnumber 1]]Marina Biotech, Inc. (OTCMKTS:MRNA) was once listed on the NASDAQ market and seemed to be a pretty solid company, as well as a good investment choice. Things over the years have changed and [[tagnumber 2]]MRNA[[tagnumber 3]] is listed in the OTC market database for quite some time.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]The company’s market cap is also quite small compared to other biotech companies that are traded at the over–the–counter markets. Especially when you consider the fact that the numbers contained in the balance sheet of their report for the first quarter of the year don’t look that bad.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 11]] [[tagnumber 12]]cash: $1.82 million[[tagnumber 13]] [[tagnumber 12]]current assets: $2.51 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $1.94 million[[tagnumber 13]] [[tagnumber 12]]quarterly revenues: $0[[tagnumber 13]] [[tagnumber 12]]quarterly net loss: $9 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Yes, the net loss seems a bit steep and the lack of revenues is discouraging, but [[tagnumber 2]]MRNA[[tagnumber 3]] has some decent cash positions and the liabilities aren’t that big compared to other entities with much higher market valuation.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]On June 10 the company announced that it has managed to expand its European and Canadian patent protection of the SMARTICLES nucleic acid delivery technology that [[tagnumber 2]]MRNA[[tagnumber 3]] has developed, but that didn’t do much for the company stock.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]This Wednesday [[tagnumber 2]]MRNA[[tagnumber 3]] filed an 8–K concerning the withdrawal of a Registration Statement Form S–1 (Reg. No. 333–201480), originally filed on January 14, 2015. This is due to “recent changes in the Company’s financing plans” and probably has something to do with the licensing agreement which we wrote about in our previous article.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]This led to a 10.99% gain in yesterday’s session and we saw [[tagnumber 2]]MRNA[[tagnumber 3]] close at $0.505. The volume was the biggest since the beginning of the year and the 571 thousand shares that changed their owners generated $288 thousand in daily trade value.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]][[tagnumber 2]]MRNA[[tagnumber 3]] is doing very well today and we might see it get even higher. Still, that doesn’t mean that you should skip on doing your due diligence and weighing out the risks before putting any money on the line.[[tagnumber 4]]